Valuation: Cipher Pharmaceuticals Inc.

Market Cap 343M 244M 218M 200M 182M 22.89B 354M 2.41B 960M 12.22B 914M 895M 38.57B P/E 2026 *
12x
P/E 2027 * 11.1x
Enterprise Value 343M 244M 218M 200M 182M 22.89B 354M 2.41B 960M 12.22B 914M 895M 38.57B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4.22x
Free-Float
57.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week+3.52%
Current month+3.52%
1 month-2.53%
3 months-23.89%
6 months-24.53%
Current year-10.29%
1 week 12.76
Extreme 12.76
13.59
1 month 12.76
Extreme 12.76
13.81
Current year 12.76
Extreme 12.76
20.56
1 year 12.76
Extreme 12.76
20.56
3 years 4.35
Extreme 4.35
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 TaxCompany -133,245 0.5243%
9/30/26 TaxCompany 133,245 0.5243%
9/29/26 Option

Director

5,000 0.0197%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+3.52%-8.81%+209.15% 244M
-0.79%-4.48%+44.44%+127.49% 1,206B
+1.43%+1.11%+47.73%+82.08% 665B
+1.07%-1.21%+32.99%+106.31% 515B
-0.36%-3.25%+47.17%+64.58% 381B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 307B
-0.80%-0.21%+8.54%+35.56% 289B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 207B
Average +0.07%-1.03%+35.48%+89.82% 418B
Weighted average by Cap. -0.04%-1.96%+42.24%+88.39%

Financials

2026 *2027 *
Net sales 70.85M 50.26M 45.07M 41.19M 37.6M 4.72B 73.08M 497M 198M 2.52B 189M 185M 7.96B 81.35M 57.71M 51.76M 47.3M 43.18M 5.42B 83.92M 570M 227M 2.89B 217M 212M 9.14B
Net income 27.7M 19.65M 17.62M 16.11M 14.7M 1.85B 28.57M 194M 77.41M 985M 73.75M 72.17M 3.11B 31.76M 22.53M 20.21M 18.47M 16.86M 2.12B 32.76M 223M 88.76M 1.13B 84.56M 82.75M 3.57B
Net Debt - -
Projected Income Statement - Annual - Cipher Pharmaceuticals Inc.
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-11-06 $13.51 +1.43% 20,688
26-11-05 $13.32 +2.23% 14,920
26-11-04 $13.03 -0.31% 33,468
26-11-03 $13.07 -0.98% 9,579
26-11-02 $13.20 +1.15% 9,095
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.51CAD
Average target price
19.45CAD
Spread / Average Target
+43.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipher Pharmaceuticals Inc.